摘要
生物制剂的应用极大地改变了克罗恩病的传统治疗模式。近10余年来,多种新型生物制剂被批准用于常规治疗无效的难治性克罗恩病的治疗,这些生物制剂从最初的抗肿瘤坏死因子-α(TNF-α)单抗发展到后来的抗白细胞黏附分子单抗,显示了基础研究向临床应用的转化以及临床疗效和安全性;但同时一些问题诸如生物制剂失应答、最佳治疗策略、临床治疗的成本-效益比和效益-风险比也逐渐得以关注。
Introduction of biological agents for the treatment of Crohn＇s disease （CD） has led to a transformation of the treat- ment paradigm. Through the use of biologics for more than a decade, several novel biological compounds have been approved for application in patients with CD refractory to conventional treatment. These biological agents evolve from the previous anti- TNF-α monoclonal antibodies to recent anti-leukocyte adhesion molecule monoclonal antibodies and display clinical efficacy and safe profile. However, debatable questions are increasingly focused on loss of response, optimal treatment regimens, cost- efficiency and efficiency-risk ratios during biological treatments of CD.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2014年第9期867-870,共4页
Chinese Journal of Practical Internal Medicine
基金
国家自然科学基金(81070280,81270467)
关键词
生物制剂
抗TNF-α单抗
克罗恩病
抗白细胞黏附分子单抗
biological agents
anti-TNF-α mAb
Crohn＇s disease
anti-leukocyte adhesion molecules monoclonal antibody
